This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: The Innovations of Minghai Fang
Introduction
Minghai Fang is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antidiabetic compounds. His work focuses on innovative solutions for managing Type 2 diabetes mellitus and related conditions.
Latest Patents
Minghai Fang holds a patent for [7,6]-fused bicyclic antidiabetic compounds. These novel compounds, characterized by their structural formula, act as agonists of the G-protein coupled receptor 40 (GPR40). They may be beneficial in the treatment, prevention, and suppression of diseases mediated by this receptor. The compounds are particularly useful for addressing Type 2 diabetes mellitus and associated conditions such as obesity and lipid disorders, including mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
Career Highlights
Minghai Fang is currently employed at Merck Sharp & Dohme Corporation, a leading global healthcare company. His role involves research and development in the pharmaceutical sector, where he applies his expertise to create effective treatments for diabetes and related health issues.
Collaborations
Minghai Fang has collaborated with esteemed colleagues such as Harry R Chobanian and Duane E DeMong. These partnerships enhance the research and development process, fostering innovation in the pharmaceutical industry.
Conclusion
Minghai Fang's contributions to the field of antidiabetic compounds highlight his commitment to improving healthcare outcomes. His innovative work at Merck Sharp & Dohme Corporation continues to pave the way for advancements in diabetes treatment.